Summit 主导药物获中国标签扩展批准 (SMMT:NASDAQ)
· seekingalpha.com
Summit Therapeutics (SMMT) 股价上涨，因中国批准了与 Akeso (AKESF) 合作开发的主导药物 ivonescimab 的标签扩展。在此了解更多。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...